Seventeen organizations, including the AHA, today urged Congress to resist any attempts from the pharmaceutical industry to undo during the lame duck session provisions included in the Bipartisan Budget Act to make prescription drugs more affordable for seniors. The legislation closes the Medicare Part D coverage gap or “doughnut hole” one year earlier and requires higher drug manufacturer discounts on brand name prescription drugs while enrollees are in the coverage gap.

 

“Now, rather than build off the progress Congress has made to lower out-of-pocket costs, brand-name drug manufacturers are continuing to actively work to reverse this change at the expense of patients and taxpayers by reducing the manufacturer discount from 70 to 63 percent,” the organizations said in a letter to congressional leaders. “Moving forward with such a proposal during the lame duck session would dramatically increase costs for seniors and taxpayers, who will be forced to subsidize what amounts to a multi-billion-dollar bailout for the price-gouging pharmaceutical industry.”

 

The Campaign for Sustainable Rx Pricing, of which the AHA is a founding member, also launched an ad campaign today calling on Congress to keep its commitment to lower drug prices.

Related News Articles

Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District…